Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: A six-year experience at a university referral center

Retina

Volumn 31, Issue 4, 2011, Pages 662-668

  Moshfeghi, Andrew A ^a,b   Rosenfeld, Philip J ^a,b   Flynn Jr , Harry W ^a,b   Schwartz, Stephen G ^a,b   Davis, Janet L ^a,b   Murray, Timothy G ^a,b   Smiddy, William E ^a,b   Berrocal, Audina M ^a,b   Dubovy, Sander R ^a,b   Lee, Wen Hsiang ^a,b   Albini, Thomas A ^a,b   Lalwani, Geeta A ^a,b   Kovach, Jaclyn L ^a,b   Puliafito, Carmen A ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; ENDOPHTHALMITIS; HAND MOVEMENT; HUMAN; MEDICAL RECORD REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; UNIVERSITY HOSPITAL; VISUAL ACUITY;

ACADEMIC MEDICAL CENTERS; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; AQUEOUS HUMOR; BACTERIA; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 79955065175     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821067c4     Document Type: Article

References (21)

1. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly patients. Arch Ophthalmol 2008;126:1748-1754.
2. Schwartz SG, Flynn HW Jr, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother 2009;10:1-8.
3. El-Ashry MF, Dhillon B. The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2009;29:720-721; author reply 721-722.
4. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116:1225.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351: 2805-2816. (Pubitemid 40051904)
6. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-605.
7. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;133:633-642.
8. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567. (Pubitemid 351589565)
9. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009;3: 2187-2193.
10. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
11. Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
12. Brown DM, MichelsM, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
13. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthlamol 2008;145: 862-874.
14. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90: 1344-1349. (Pubitemid 44702055)
15. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
16. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthlamol 2008;246:81-87. (Pubitemid 350167096)
17. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 2010;30:1051-1057.
18. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19. (Pubitemid 39391785)
19. Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
20. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363. (Pubitemid 351733229)
21. Soudry S, Lowenestein A, Moisseiv J. Repeated noninfectious endophthalmitis after intravitreal administration of bevacizumab: a report of two cases. Retin Cases Brief Rep 2010;4:220-223.